155 related articles for article (PubMed ID: 16948881)
1. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.
Kiliç M; Göçmen E; Tez M; Ertan T; Keskek M; Koç M
Can J Surg; 2006 Aug; 49(4):241-4. PubMed ID: 16948881
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
Maithel SK; Maloney S; Winston C; Gönen M; D'Angelica MI; Dematteo RP; Jarnagin WR; Brennan MF; Allen PJ
Ann Surg Oncol; 2008 Dec; 15(12):3512-20. PubMed ID: 18781364
[TBL] [Abstract][Full Text] [Related]
3. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
4. High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer.
Alexakis N; Gomatos IP; Sbarounis S; Toutouzas K; Katsaragakis S; Zografos G; Konstandoulakis MM
Eur J Surg Oncol; 2015 Feb; 41(2):265-9. PubMed ID: 25266999
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
6. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.
Zhang S; Wang YM; Sun CD; Lu Y; Wu LQ
World J Gastroenterol; 2008 Jun; 14(23):3750-3. PubMed ID: 18595144
[TBL] [Abstract][Full Text] [Related]
8. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
10. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.
Tamm EP; Loyer EM; Faria S; Raut CP; Evans DB; Wolff RA; Crane CH; Dubrow RA; Charnsangavej C
Abdom Imaging; 2006; 31(5):568-74. PubMed ID: 16465578
[TBL] [Abstract][Full Text] [Related]
11. Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis.
McGahan W; Waterhouse MA; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Burmeister EA; Jordan SJ; Neale RE
Pancreatology; 2020 Oct; 20(7):1458-1464. PubMed ID: 32868184
[TBL] [Abstract][Full Text] [Related]
12. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
Luo G; Xiao Z; Long J; Liu Z; Liu L; Liu C; Xu J; Ni Q; Yu X
J Gastrointest Surg; 2013 Dec; 17(12):2092-8. PubMed ID: 24146342
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prediction of complete resection in pancreatic cancer.
Shah D; Fisher WE; Hodges SE; Wu MF; Hilsenbeck SG; Charles Brunicardi F
J Surg Res; 2008 Jun; 147(2):216-20. PubMed ID: 18498873
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
15. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
16. Experience with laparoscopic ultrasonography for defining tumour resectability in carcinoma of the pancreatic head and periampullary region.
Taylor AM; Roberts SA; Manson JM
Br J Surg; 2001 Aug; 88(8):1077-83. PubMed ID: 11488793
[TBL] [Abstract][Full Text] [Related]
17. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
18. Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma.
Ahmad NA; Lewis JD; Siegelman ES; Rosato EF; Ginsberg GG; Kochman ML
Am J Gastroenterol; 2000 Aug; 95(8):1926-31. PubMed ID: 10950037
[TBL] [Abstract][Full Text] [Related]
19. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
20. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer.
Satoi S; Yanagimoto H; Toyokawa H; Inoue K; Wada K; Yamamoto T; Hirooka S; Yamaki S; Yui R; Mergental H; Kwon AH
Pancreas; 2011 Apr; 40(3):426-32. PubMed ID: 21206325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
